Emerging technology could provide key advances in pre-op planning and intraoperative management in endovascular surgery.
The addition of new 3D imaging capabilities to a mobile C-arm system may enhance procedure planning, improve real-time intraoperative guidance, and significantly reduce procedure times for endovascular surgery procedures.
Endovascular surgeons who use the Zenition image-guided therapy mobile C-arm system (Philips) will now have advanced 3D image guidance capabilities thanks to a new partnership agreement between Philips and the United Kingdom-based company Cydar, which specializes in cloud-based procedure map software.
Philips says combining the Zenition system’s versatility and innovative image capture with the artificial-intelligence (AI)-enabled technology and patient-specific 3D mapping of target vasculature offered with Cydar EV Maps may lead to greater efficiency, safety, and improved outcomes. Not only does the technology bolster procedure planning, Philips notes the real-time updates of the 3D mapping can provide enhanced guidance for addressing findings encountered during endovascular procedures.
The integration of these technologies could lead to a 50 percent reduction in radiation exposure and a greater than 20 percent reduction in procedure times, according to Philips.
“With Philips’ integrated portfolio, using validated AI and cloud technologies, we can facilitate collaborative care to optimize surgical pathways,” said Karim Boussebaa, the General Manager of Image Guided Therapy Systems at Philips. “Philips has a strong global network of mobile surgery systems and recognizes that Cydar’s EV Maps solution can play a key role in further improving our integrated offering for endovascular procedures.”
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.